BDBM416870 1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethylamino)(2,3-dihydroxyphenyl)methyl)phenyl)-3-methyl-1H-pyrazole-5-carboxamide::US10329260, Compound 150f::US10633345, Compound 150f::US10689346, Compound 150f::US11203574, Compound 150f::US11230530, Compound 150f::US11708332, Compound 150f

SMILES Cc1cc(C(=O)Nc2cccc(c2)C(NCC2CC2)c2cccc(O)c2O)n(n1)-c1cccc(CN)c1

InChI Key InChIKey=VPKURNQNFXHFDB-UHFFFAOYSA-N

Data  7 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 416870   

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416870(US10329260, Compound 150f | 1-(3-(Aminomethyl)phen...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/17/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416870(US10329260, Compound 150f | 1-(3-(Aminomethyl)phen...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416870(US10329260, Compound 150f | 1-(3-(Aminomethyl)phen...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416870(US10329260, Compound 150f | 1-(3-(Aminomethyl)phen...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416870(US10329260, Compound 150f | 1-(3-(Aminomethyl)phen...)
Affinity DataKi:  25.1nMAssay Description:Plasma kallikrein activity assay. The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416870(US10329260, Compound 150f | 1-(3-(Aminomethyl)phen...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416870(US10329260, Compound 150f | 1-(3-(Aminomethyl)phen...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent